Gastrointestinal Endoscopy
Volume 70, Issue 2 , Pages 225-228 , August 2009

GI bleeding: problems that persist

References 

  1. Loperfido S, Baldo V, Piovesana E, et al. Changing trends in acute upper-GI bleeding: a population-based study. Gastrointest Endosc. 2009;70:212–224
  2. Gralnek IM, Barkun AN, Bardou M. Management of acute bleeding from a peptic ulcer. N Engl J Med. 2008;359:928–937
  3. Standards of Practice Committee. ASGE Guideline: the role of endoscopy in the management of variceal hemorrhage. Gastrointest Endosc. 2005;62:651–655
  4. ASGE Standards of Practice Committee. ASGE guideline: role of endoscopy in acute nonvariceal upper-GI hemorrhage. Gastrointest Endosc. 2004;60:497–503
  5. Bardou M, Toubouti Y, Benhaberou-Brun D, et al. Meta-analysis: proton pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther. 2005;21:677–686
  6. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2006;1:CD002094
  7. McCarthy DM. Management of bleeding peptic ulcer: current status of intravenous proton pump inhibitors. Best Pract Res Clin Gastroenterol. 2004;18(Suppl 1):7–12
  8. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II. Randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–65
  9. Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology. 2007;132:2320–2327
  10. Sonnenberg A. Time trends of ulcer mortality in non-European countries. Am J Gastroenterol. 2007;102:1101–1107
  11. Rupnow MFT, Shacter RD, Owens DK, et al. A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States. Emerging Infect Dis. 2000;6:228–237
  12. Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and non-ulcer upper and lower gastrointestinal bleeding/perforation. Gastroenterology. 1992;103:8629–8637
  13. Stack WA, Atherton JC, Hawkey GM, et al. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther. 2002;16:497–506
  14. Pritchard JP, Kitchingman GK, Walt RP, et al. Human gastric mucosal bleeding induced by low-dose aspirin but not by warfarin. Br Med J. 1989;298:493–496
  15. McCarthy DM. The comparative toxicity of non-steroidal anti-inflammatory drugs. Am J Med. 1999;107:37–47
  16. Rahme E, Nedjar H, Bizzi A, et al. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study. Aliment Pharmacol Ther. 2007;26:1387–1398
  17. Gladding PA, Webster MWI, Farrell HB, et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol. 2008;101:1060–1063
  18. Cryer B, Feldman M. Effects of very low dose daily, long term aspiring therapy on gastric, duodenal and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999;117:17–25
  19. McCarthy DM. Non-steroidal anti-inflammatory drugs—the clinical dilemmas. Scand J Gastroenterol. 1992;192:9–16
  20. Kurata J, Abbey DE. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalization. J Clin Gastroenterol. 1990;12:260–266
  21. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–1528
  22. McCarthy DM. Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?. Eur J Surg. 2002;587:89–99
  23. Huang J-Q, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet. 2002;359:14–22
  24. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal adverse clinical events with non-selective NSAID or coxib use. Gastroenterology. 2003;124:288–292
  25. FDA raising approval bar for NSAID/PPI combos: end-points under review. The Pink Sheet. 2008;70:31–32
  26. Barrett NE, Holbrook L, Jones S, et al. Future innovations in anti-platelet therapies. Br J Pharmacol. 2008;154:918–939
  27. Fork FT, Lafolie P, Toth E, et al. Gastro-duodenal tolerance of 75 mg clopidogrel versus 325 mg of aspiring in healthy volunteers. Scand J Gastroenterol. 2000;35:464–469
  28. Bhatt DI, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of anti-platelet therapy and NSAID use. Am J Gastroenterol. 2008;103:2890–2897
  29. Chan FKL, Ching JYL, Hung LCT, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005;352:238–244
  30. Lai K-C, Chu K-M, Hui W-M, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol. 2006;4:860–865
  31. Aubert RE, Epstein RS, Teagarden JR, et al. Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel medco outcomes study. [abstract] Circulation. 2008;118(S815):3998
  32. Juurlink DN, Gomes T, Ko DT, et al. Population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009 Jan 28;[Epub ahead of print]
  33. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). Available at: http://www.fda.gov/cder/drug/early_comm/clopidogrel_bisulfate.htm. Accessed January 27, 2009.
  34. Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal hemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther. 2006;23:937–944
  35. De Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy. Arch Gen Psychiatry. 2008;65:795–803

PII: S0016-5107(08)03429-9

doi: 10.1016/j.gie.2008.12.247

Gastrointestinal Endoscopy
Volume 70, Issue 2 , Pages 225-228 , August 2009

Article Tools